# Revision Breast Surgery and Management of Complications

## Introduction
Breast implant-related complications are common and often require surgical revision. Revision surgery encompasses capsular contracture management, implant malposition correction, implant exchange, and conversion to autologous reconstruction. Emerging concerns include BIA-ALCL and breast implant illness (BII). Understanding the biology of implant-related complications is essential for prevention and management.

## Capsular Contracture

### Pathophysiology
All implants develop a fibrous capsule (normal foreign body response). Capsular contracture is excessive fibrosis and contraction causing firmness, distortion, and pain. Etiology is multifactorial: subclinical infection (biofilm), hematoma, seroma, radiation, texturing type. Biofilm hypothesis: bacterial colonization of the implant surface drives chronic inflammation and fibrosis.

### Baker Classification
**Grade I**: soft, natural appearance and feel. **Grade II**: slightly firm but normal appearance. **Grade III**: firm, visible distortion of breast shape. **Grade IV**: hard, painful, significant distortion, cold to touch. Grades III and IV typically require surgical treatment.

### Risk Factors
Radiation therapy (strongest risk factor; 30-50% incidence). Smooth subglandular placement (higher than submuscular). Hematoma/seroma. Infection. Silicone gel leak/rupture. Periareolar incision (higher biofilm introduction theoretically).

### Prevention Strategies
**14-point plan** (Adams): Preoperative antibiotics. Inframammary fold approach (lowest biofilm risk). Atraumatic tissue handling.

Pocket irrigation (triple antibiotic solution or Betadine). No-touch technique (minimal implant handling). Nipple shields to prevent contact with ductal bacteria. Glove change before implant handling.

Submuscular/dual-plane placement. Layered closure. Textured surface consideration (counterbalanced by BIA-ALCL risk). Postoperative: textured implants historically lower contracture rates but carry BIA-ALCL risk; smooth implants now preferred by many.

### Treatment
**Capsulotomy**: scoring or releasing the capsule to enlarge the pocket (open or closed). Closed capsulotomy: external manual compression to rupture the capsule; NOT recommended (risk of implant rupture, hematoma). Open capsulotomy: surgical release with pocket modification. **Capsulectomy**: complete removal of the capsule.

En bloc capsulectomy: capsule removed as a single specimen with the implant (mandatory for BIA-ALCL). Total capsulectomy: capsule removed but not necessarily en bloc. **Site change**: move implant to a new pocket plane (e.g., subglandular to submuscular or vice versa). **Implant exchange**: replace with a different implant type (silicone to saline, textured to smooth).

**Conversion to autologous**: for recurrent contracture, particularly in irradiated patients. **ADM interposition**: acellular dermal matrix placed around the implant may reduce recurrence.

## Implant Malposition

### Types

| Malposition | Description | Common Cause | Correction |
|-------------|-------------|--------------|------------|
| Superior displacement | Implant too high | Inadequate lower pole release, capsular contracture | Inferior capsulotomy, pocket expansion |
| Inferior (bottoming out) | Implant too low | IMF disruption/attenuation | IMF reconstruction with capsulorrhaphy ± ADM |
| Lateral displacement | Implant migrates laterally | Excessive lateral pocket dissection | Lateral capsulorrhaphy ± ADM |
| Medial (symmastia) | Implants meet in midline | Over-release of medial pocket | Medial capsulorrhaphy + ADM reinforcement |
| Double bubble | Dual contour at native IMF | Implant below native IMF; constricted breast | IMF release or site change |

**Superior displacement/ride**: implant too high; often due to inadequate lower pole release or capsular contracture. **Inferior displacement (bottoming out)**: implant too low; IMF disrupted or attenuated. **Lateral displacement**: implant migrates laterally, especially when supine. **Medial displacement (symmastia)**: implants meet in the midline; overrelease of medial pocket; "uniboob" deformity. **Double bubble**: implant visible below the native IMF creating a dual contour line.

### Correction Techniques
**Capsulorrhaphy**: internal suture plication of the capsule to narrow the pocket in the desired direction. **Neosubpectoral pocket**: complete capsulectomy and creation of a new submuscular pocket. **ADM reinforcement**: acellular dermal matrix sewn to chest wall to reinforce weakened pocket boundaries. **IMF reconstruction**: suture fixation of the capsule/ADM to the chest wall at the appropriate IMF level. Symmastia: difficult correction; requires medial capsulorrhaphy, often with ADM reinforcement.

## Animation Deformity
Breast distortion during pectoralis major contraction (subpectoral implants). Due to implant displacement by the overlying muscle. Bothers patients especially during exercise. **Treatment options**: 
Conversion to prepectoral placement (most definitive). Partial pectoralis muscle release (muscle division). Fat grafting to soften visible muscle edges. Botox injection to pectoralis (temporary).

<image>Illustration showing four common implant malposition types in breast reconstruction/augmentation, each shown on a frontal view of the chest. Panel A: Superior displacement with the implant riding too high, leaving an empty lower pole and double-bubble deformity. Panel B: Bottoming out with the implant displaced inferiorly below the native inframammary fold, nipple pointing upward. Panel C: Lateral displacement with the implant migrated laterally, creating excessive lateral fullness and medial deficiency. Panel D: Symmastia with both implants meeting in the midline, loss of the intermammary cleft, and a "uniboob" appearance. Each panel has arrows indicating the direction of malposition and the ideal corrected position shown in dotted outline.</image>

## Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

### Overview
Rare T-cell non-Hodgkin lymphoma arising in the capsule surrounding breast implants. Not a breast cancer; it is a lymphoma of the peri-implant capsule. Strongly associated with textured implants (especially macro-textured/Biocell). Estimated risk: 1:2,000 to 1:86,000 for macro-textured implants (varies by surface type). Median time to presentation: 8-10 years after implant placement.

### Presentation
Late-onset peri-implant seroma (most common; >1 year after implant placement). Breast swelling, pain, mass. Less commonly: axillary lymphadenopathy, systemic symptoms.

### Diagnosis
Aspiration of peri-implant fluid: send for cytology AND CD30 immunohistochemistry. CD30-positive, ALK-negative large cells confirm diagnosis. PET/CT for staging. Seroma fluid: cell block analysis.

### Staging (MD Anderson/NCCN)
**Stage I**: confined to the effusion or capsular luminal surface. **Stage II**: capsular invasion. **Stage III**: beyond the capsule into breast tissue or regional lymph nodes. **Stage IV**: distant metastasis.

### Treatment
**Stage I (most patients)**: en bloc capsulectomy with implant removal is curative. Complete surgical excision = excellent prognosis (5-year OS >90%). No chemotherapy or radiation required for confined disease. **Advanced stage**: chemotherapy (CHOP-based), possible radiation.

Contralateral implant: removal with capsulectomy recommended (risk of bilateral disease). Long-term surveillance after treatment.

### Prevention
Informed consent regarding BIA-ALCL risk with textured implants. Trend toward smooth implants in reconstruction and augmentation. FDA recalls/restrictions on certain macro-textured implants (Allergan Biocell recalled 2019).

## Breast Implant Illness (BII)

### Overview
Patient-reported systemic symptoms attributed to breast implants. Symptoms: fatigue, cognitive difficulties ("brain fog"), joint pain, hair loss, skin rashes, autoimmune-like symptoms. No established diagnostic criteria or biomarker. Controversial: not recognized as a distinct medical diagnosis by major medical organizations. Growing patient advocacy and awareness.

### Evaluation
Thorough history and physical examination. Autoimmune panel, inflammatory markers, thyroid function. Rule out other medical conditions. Psychiatric/psychological assessment when appropriate.

### Management
Explantation with capsulectomy (en bloc when possible): many patients report symptom improvement. Prospective studies show mixed results; placebo effect and selection bias are confounding factors. Informed, shared decision-making; do not dismiss patient concerns. If explantation chosen, discuss reconstruction options vs. no replacement.

## Implant Rupture

### Saline Implants
Rupture = immediate deflation (clinically obvious). Saline absorbed harmlessly. Treatment: explantation with exchange or conversion.

### Silicone Gel Implants
"Silent rupture": may be asymptomatic for years. Intracapsular rupture: gel contained within the intact capsule ("linguine sign" on MRI). Extracapsular rupture: gel escapes the capsule into breast tissue; may cause granulomas, lymphadenopathy. Diagnosis: MRI (most sensitive imaging modality); "linguine sign" = collapsed shell within gel. Treatment: explantation with capsulectomy; implant exchange if desired.

## Rippling
Visible or palpable undulations of the implant surface through the skin. More common with: saline implants, textured surface, thin soft tissue coverage, subglandular placement. Treatment: conversion to submuscular, fat grafting over the implant, exchange to cohesive silicone gel, ADM coverage (prepectoral with full ADM wrap).

## Clinical Pearls
En bloc capsulectomy is mandatory when BIA-ALCL is suspected; incomplete removal is associated with recurrence — always send the entire capsule and fluid for histopathology and CD30 staining. Any late-onset seroma (>1 year post-implant) should be aspirated and sent for CD30 immunohistochemistry to rule out BIA-ALCL before assuming it is benign. Capsular contracture is best prevented rather than treated; adherence to the 14-point plan (pocket irrigation, no-touch technique, submuscular placement) significantly reduces incidence.

For recurrent capsular contracture after revision, strongly consider conversion to autologous reconstruction rather than repeated implant exchanges. When correcting implant malposition, ADM reinforcement provides a biological scaffold that significantly reduces recurrence compared to capsulorrhaphy alone. Breast implant illness is a real concern for many patients regardless of its contested medical status; an empathetic, patient-centered approach with informed consent regarding explantation is essential.

## References
- Adams WP Jr. Capsular contracture: what is it? What causes it? How can it be prevented and managed? Clin Plast Surg. 2009;36(1):119-126.
- Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34(2):160-168.
- Leberfinger AN, Behar BJ, Williams NC, et al. Breast implant-associated anaplastic large cell lymphoma: a systematic review. JAMA Surg. 2017;152(12):1161-1168.
- Tang SY, Israel JS, Afifi AM. Breast implant illness: symptoms, patient concerns, and the power of social media. Plast Reconstr Surg. 2017;140(5):765e-766e.
- Spear SL, Baker JL. Classification of capsular contracture after prosthetic breast reconstruction. Plast Reconstr Surg. 1995;96(5):1119-1123.
- de Boer M, van Leeuwen FE, Hauptmann M, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol. 2018;4(3):335-341.